HemaCare Corp. has entered into a partnership with Tissue Solutions Ltd. to supply customers with a wider range of disease-state biomaterial for research.
The Northridge-based HemaCare and Tissue Solutions in Glasgow, Scotland, announced the partnership Thursday.
HemaCare customers will now have access to pathology-verified frozen tissues, which are preferred for long-term preservation, as well as tumor tissues and dissociated tumor cells that can be hard to source, the Northridge company said in a release.
“HemaCare has seen a high demand from scientists and clinical researchers for blood and other tissue samples from diseased patients,” Lou Juliano, senior vice president of HemaCare’s global sales and business development, said in a statement. “Tissue Solutions is already one of HemaCare’s preferred European distributors and this expanded partnership allows our customers to readily access over 110 million banked human samples sourced through a network of more than 500 qualified suppliers.”
With expanded offerings that benefit both companies, researchers will be able to access ideal samples faster, leading to accelerated research timelines.
Shares of HemaCare closed Thursday down 25 cents, or 1.8 percent, to $13.75 on the over-the-counter market.